ELOX: Eloxx Pharmaceuticals, Inc. Stock Price, Chart & Stats

Market snapshot

Dow Jones0.98%53,277.01+517.81 S&P 5000.43%7,674.37+33.21 Nasdaq0.43%26,180.46+113.26 Russell0.85%3,017.87+25.44 VIX4.96%15.88+0.75

Evelo Biosciences, Inc.$0.00 Cyclerion Therapeutics, Inc.$3.89 Avenue Therapeutics, Inc.$0.26 Aridis Pharmaceuticals, Inc.$0.00 Synlogic, Inc.$1.20

In the news

Financials

Income Statement

Dec 2022

Mar 2023

Jun 2023

Sep 2023

RevenueNet income

(USD)	Sep 2023	Y/Y change
Revenue	0.00	—
Operating expense	—	—
Net income	-3.59M	—
Net profit margin	—	—
Earnings per share	—	—
EBITDA	—	—
Effective tax rate	—	—

ELOX stock return: YTD, 1 year, 5 years, 10 years

Period	Total return
All-time high	$20.98 (Aug 2026)

Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.

See what $1,000 in ELOX would be worth today ›

Key facts

Does Eloxx Pharmaceuticals, Inc. pay a dividend?

No. Eloxx Pharmaceuticals, Inc. has not paid a dividend in the past 12 months.

What exchange does Eloxx Pharmaceuticals, Inc. stock trade on?

Eloxx Pharmaceuticals, Inc. stock trades on NASDAQ under the ticker symbol ELOX.

What sector is Eloxx Pharmaceuticals, Inc. in?

Eloxx Pharmaceuticals, Inc. is part of the Healthcare sector.

What is Eloxx Pharmaceuticals, Inc.'s market cap?

Eloxx Pharmaceuticals, Inc. has a market cap of 72.08M USD, based on the latest quote.

StockUS listed securityUS headquartered

Previous close$18.04

Day range$18.04 - 23.40

Year range$8.20 - 23.40

Market cap72.08M USD

Avg Volume60.54K

P/E ratio5.96

Primary exchangeNASDAQ

About

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.

Keep browsing

You may be interested in

ELOX: Eloxx Pharmaceuticals, Inc. Stock Price, Chart & Stats | Folivue